Use of autologous serum eyedrops for the treatment of ocular surface disease: first US experience in a large population as an insurance-covered benefit.Cyril A Dalmon, Naveen S Chandra, Bennie H Jeng
No abstract text is available yet for this article.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
You can now claim free CME credits for this literature searchClaim now